Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenThe influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerPre-clinical and clinical review of vorozole, a new third generation aromatase inhibitorAltering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerIndirect androgen doping by oestrogen blockade in sports.Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
P2860
Q24239985-4B422A7D-9D75-47FC-95AF-8B7639C8F45EQ24246391-20A3026D-59E8-4D48-BD1B-23A579C5BEDEQ24683853-04CABC33-CB36-49FC-8322-73319250B895Q29543011-E09C85BB-FBCC-479F-8855-C595A5AB97BCQ33871478-4AAB41D2-1582-42A6-AC03-A5E95A36C99CQ35776951-E988AD24-B2CF-42EC-988A-C5A651907E8EQ35977200-E4F5F7B8-E740-445A-85F2-8C3C89DEAEDEQ35979241-D1F735F7-63AD-4D0F-A867-FA1646243860Q35984346-9E17447B-C909-483E-9ACF-4EC23AB7D630Q35993244-A9A33ECF-C491-4CF5-9EFF-24288B492B28Q36135060-B68F2B53-78CD-4E3C-A927-76A3C26DC300Q36138879-B5C4D787-7616-436E-9F44-BB8100548818Q36432163-8908A4D7-71D5-4093-A848-3340BA3D34D2Q36736110-E3903272-1E9A-41B1-8CB1-70F5C2D30A65Q37025619-12176DBA-2E94-4BF3-85C7-33F3D65EE106Q41463849-A5B08091-D1B7-44DB-8050-4B0C19EB1664
P2860
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Potency and selectivity of the ...... pausal breast cancer patients.
@en
Potency and selectivity of the ...... pausal breast cancer patients.
@nl
type
label
Potency and selectivity of the ...... pausal breast cancer patients.
@en
Potency and selectivity of the ...... pausal breast cancer patients.
@nl
prefLabel
Potency and selectivity of the ...... pausal breast cancer patients.
@en
Potency and selectivity of the ...... pausal breast cancer patients.
@nl
P2093
P2860
P1476
Potency and selectivity of the ...... pausal breast cancer patients.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2265.1990.TB00906.X
P577
1990-05-01T00:00:00Z